Skip to content

Company · founded 2017

Tango Therapeutics (United States)

Cambridge, United States · tangotx.com

Manage this page

Citations, last 5 years: 691
Works, last 5 years: 85
h-index: 56
Scientists listed: 72
Grants since 2016: 8

Grants received

2025–2027 · research · R43

The Avidimer Platform - a molecular toolbox to accelerate proximity research and drug discovery

Brian Kenneth Kay · Tango Therapeutics (United States) · funded by National Institutes of Health

$314.4k

2023–2025 · research · R43

High-throughput profiling of proteases with phage and arrays

Brian Kenneth Kay · Tango Therapeutics (United States) · funded by National Institutes of Health

$256.8k

2023–2025 · research · R43

Generating fast-on rate reagents for lateral flow assays to detect HCV

Brian Kenneth Kay · Tango Therapeutics (United States) · funded by National Institutes of Health

$275.6k

2022–2024 · research · R43

Building a pipeline to generate affinity reagents to phosphothreonine epitopes

Brian Kenneth Kay · Tango Therapeutics (United States) · funded by National Institutes of Health

$222.9kMonoclonal and Polyclonal Antibodies Research

2021–2022 · research · R43

Building a Toolbox to Study the SARS-CoV-2 Proteome

Brian Kenneth Kay · Tango Therapeutics (United States) · funded by National Institutes of Health

$222.3k

2019–2021 · research · R41

Array Based Affinity Selection

Brian Kenneth Kay · Tango Therapeutics (United States) · funded by National Institutes of Health

$224kAdvanced Biosensing Techniques and Applications

2019–2021 · research · R41

Array Based Affinity Selection

Brian Kenneth Kay · Tango Therapeutics (United States) · funded by National Institutes of Health

$183.3kAdvanced Biosensing Techniques and Applications

2018–2019 · research · R41

Generating sandwich assays through MegaSTAR

Brian Kenneth Kay · Tango Therapeutics (United States) · funded by National Institutes of Health

$223.6k